Medicine · Neurology · Neurodegenerative Disease
A comprehensive analysis of 555 patients with multiple system atrophy (MSA), the largest post-mortem confirmed cohort to date, has identified robust clinical milestones for prognostic stratification. Researchers from the Queen Square Brain Bank and the PROSPECT-M-UK study found that median survival from key late-stage markers—indoor wheelchair use, gastrostomy insertion, or development of unintelligible speech—was consistently under 1.5 years, establishing these as reliable endpoints for end-of-life planning and clinical trial design. This work refines MSA prognostication by demonstrating that risk factors shift over time, with autonomic milestones dominating early disease while mobility milestones become paramount at later stages, potentially explaining previous heterogeneity in smaller studies.
Novelty: 86%
Rigor: 94%
Significance: 91%
Validity: 93%
Clarity: 88%
Update Your Briefing Preferences
Stay curious. Stay informed —
Science Briefing
Your briefing is personalized based on your selected fields, keywords, and research interests.
